Article Text

PDF
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand
  1. S R Mucha1,
  2. A Rizzani1,
  3. A L Gerbes1,
  4. P Camaj2,
  5. W E Thasler2,
  6. C J Bruns2,
  7. S T Eichhorst1,
  8. E Gallmeier1,
  9. F T Kolligs1,
  10. B Göke1,
  11. E N De Toni1
  1. 1
    University of Munich, University Hospital Grosshadern, Department of Medicine 2, Munich, Germany
  2. 2
    University of Munich, University Hospital Grosshadern, Department of Surgery, Munich, Germany
  1. Dr E N De Toni, University of Munich, University Hospital Grosshadern, Department of Medicine II, Research Lab B 5 E01 308, Marchioninistrasse 15, D-81377 Munich, Germany; enrico.detoni{at}med.uni-muenchen.de

Abstract

Background: cJun terminal kinase (JNK) is constitutively activated in most hepatocellular carcinomas (HCCs), yet its exact role in carcinogenesis remains controversial. While tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is known as a major mediator of acquired immune tumour surveillance, and is currently being tested in clinical trials as a novel cancer therapy, the resistance of many tumours to TRAIL and concerns about its toxicity in vivo represent obstacles to its clinical application. In this study we investigated whether JNK activity in HCC could contribute to the resistance to apoptosis in these tumours.

Methods: The effect of JNK/Jun inhibition on receptor-mediated apoptosis was analysed by pharmacological inhibition or RNA interference in cancer cells and non-tumour cells isolated from human liver or transgenic mice lacking a phosphorylation site for Jun.

Results: JNK inhibition caused cell cycle arrest, enhanced caspase recruitment, and greatly sensitised HCC cells but not normal hepatocytes to TRAIL. TRAIL-induced activation of JNK could be effectively interrupted by administration of the JNK inhibitor SP600125.

Conclusions: Expression and TRAIL-dependent feedback activation of JNK likely represent a mechanism by which cancer cells escape TRAIL-mediated tumour surveillance. JNK inhibition might represent a novel strategy for specifically sensitising HCC cells to TRAIL thus opening promising therapeutic perspectives for safe and effective use of TRAIL in cancer treatment.

Statistics from Altmetric.com

Footnotes

  • Funding: This study was funded by the Deutsche Forschungsgemeinschaft (DFG) grant to the KFO128 to BG, and the Förderprogramm für Forschung und Lehre (FöFoLe) of the Ludwig Maximilian University to EDT.

  • Competing interests: None.

  • Ethics approval: Tissue sample collection from human liver resections was performed according to the guidelines of the charitable state-controlled foundation Human Tissue and Cell Research.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.